The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Selective Inhibition of Lysine‐Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple‐Negative Breast Cancer Therapy
Abstract
Lysine‐specific demethylase 5A (KDM5A) has recently become a promising target for epigenetic therapy. In this study, we designed and synthesized metal complexes bearing ligands with reported demethylase and p27 modulating activities. The Rh(III) complex 1 was identified as a direct, selective and potent inhibitor of KDM5A that directly abrogate KDM5A demethylase activity via antagonizing the KDM5A‐tri‐/di‐methylated histone 3 protein–protein interaction (PPI) in vitro and in cellulo. Complex 1 induced accumulation of H3K4me3 and H3K4me2 levels in cells, causing growth arrest at G1 phase in the triple‐negative breast cancer (TNBC) cell lines, MDA‐MB‐231 and 4T1. Finally, 1 exhibited potent anti‐tumor activity against TNBC xenografts in an in vivo mouse model, presumably via targeting of KDM5A and hence upregulating p27. Moreover, complex 1 was less toxic compared with two clinical drugs, cisplatin and doxorubicin. To our knowledge, complex 1 is the first metal‐based KDM5A inhibitor reported in the literature. We anticipate that complex 1 may be used as a novel scaffold for the further development of more potent epigenetic agents against cancers, including TNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma
Banelli, B., Carra, E., Barbieri, F., Würth, R., Parodi, F., Pattarozzi, A., Carosio, R., Forlani, A., Allemanni, G., Marubbi, D., et al. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1090063 · Cited by 135
Cited by
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
The great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 761
LSD1/KDM1A inhibitors in clinical trials: advances and prospects
Fang, Y., Liao, G., & Yu, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0811-9 · Cited by 438
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Recent advances in biosensor for detection of lung cancer biomarkers
Yang, G., Xiao, Z., Tang, C., Deng, Y., Huang, H., & He, Z. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.111416 · Cited by 330
Self-citation
Metadata
- Authors
- Yang, G., Wang, W., Mok, S. W. F., Wu, C., Law, B. Y. K., Miao, X., Wu, K., Zhong, H., Wong, C., Wong, V. K. W., Ma, D., & Leung, C.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2018-07-19
- Volume
- 57
- Issue
- 40
- Pages
- 13091-13095
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2811294037
- Cited by
- 161
- References
- 1
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Inhibition of Lysine‐Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple‐Negative Breast Cancer Therapy. https://app.cochat.ai/papers/10.1002/anie.201807305
- The paper
- Yang, G., Wang, W., Mok, S. W. F., Wu, C., Law, B. Y. K., Miao, X., Wu, K., Zhong, H., Wong, C., Wong, V. K. W., Ma, D., & Leung, C. (2018). Selective Inhibition of Lysine‐Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple‐Negative Breast Cancer Therapy. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.201807305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.